LETTER TO THE EDITOR
 
TOPICS
REFERENCES (11)
1.
Maury CP, Kere J, Tolvanen R, de la Chapelle A. Finnish hereditary amyloidosis is caused by a single nucleotide substitution in the gelsolin gene. FEBS Lett 1990; 276: 75-7.
 
2.
Kiuru-Enari S, Haltia M. Hereditary gelsolin amyloidosis. Handb Clin Neurol 2013; 115: 659-81.
 
3.
Efebera YA, Sturm A, Baack EC, et al. Novel gelsolin variant as the cause of nephrotic syndrome and renal amyloidosis in a large kindred. Amyloid 2014; 21: 110-2.
 
4.
Solomon JP, Page LJ, Balch WE, Kelly JW. Gelsolin amyloidosis: genetics, biochemistry, pathology and possible strategies for therapeutic intervention. Crit Rev Biochem Mol Biol 2012; 47: 282-96.
 
5.
Nikoskinen T, Schmidt EK, Strbian D, Kiuru-Enari S, Atula S. Natural course of Finnish gelsolin amyloidosis. Ann Med 2015; 47: 506-11.
 
6.
Thompson GL, Kavanagh D. Diagnosis and treatment of thrombotic microangiopathy. Int J Lab Hematol 2022; 44 (Suppl 1): 101-13.
 
7.
Volokhina EB, Feitz WJC, Elders LM, van der Velden TJAM, van de Kar NCAJ, van den Heuvel LPWJ. Shiga toxin selectively upregulates expression of syndecan-4 and adhesion molecule ICAM-1 in human glomerular microvascular endothelium. Toxins 2020; 12: 435.
 
8.
Schaefer F, Ardissino G, Ariceta G, et al.; Global aHUS Registry. Clinical and genetic predictors of atypical hemolytic uremic syndrome phenotype and outcome. Kidney Int 2018; 94: 408-18.
 
9.
Sethi S, Theis JD, Quint P, et al. Renal amyloidosis associated with a novel sequence variant of gelsolin. Am J Kidney Dis 2013; 61: 161-6.
 
10.
Zhang Q, Wen XH, Tang SL, Zhao ZW, Tang CK. Role and therapeutic potential of gelsolin in atherosclerosis. J Mol Cell Cardiol 2023; 178: 59-67.
 
11.
Gupta AK, Chopra BS, Vaid B, et al. Protective effects of gelsolin in acute pulmonary thromboembolism and thrombosis in the carotid artery of mice. PLoS One 2019; 14: e0215717.
 
eISSN:1896-9151
ISSN:1734-1922
Journals System - logo
Scroll to top